Last updated: July 3, 2026
H. Lundbeck A/S v. Torrent Pharmaceuticals Limited (1:18-cv-00149): Litigation Summary, Patent Issues, and 2024-2025 Status
Executive summary:
The case H. Lundbeck A/S v. Torrent Pharmaceuticals Limited, No. 1:18-cv-00149 (D. Delaware) is a Hatch-Waxman dispute brought by H. Lundbeck A/S against Torrent Pharmaceuticals Limited over ANDA-type generic entry and associated patent infringement/invalidity positions tied to Lundbeck’s branded product(s) and Orange Book-listed intellectual property. Publicly accessible docket and opinion content is required to produce an accurate litigation-specific summary, including asserted patent numbers, claim charts at issue, motion history, court holdings, and any settlement/consent outcomes.
No complete, citation-grade case record is provided in the prompt, and generating an “accurate” litigation analysis without verified docket facts and patent identifications is not possible under this task’s constraints.
What patents were asserted in H. Lundbeck A/S v. Torrent (1:18-cv-00149)?
Featured snippet answer: Cannot be stated from the information provided. A litigation summary must name the asserted U.S. patents, their publication and filing families, and which claims were asserted.
Which Lundbeck Orange Book patents were targeted
- Asserted patent identification
- Orange Book listing mapping (drug, dosage form, strength)
- Linkage to Paragraph IV notices and FDA ANDA status
What Torrent’s defenses were
- Invalidity (anticipation/obviousness/§112)
- Non-infringement
- Procedural defenses (joinder, claim construction disputes)
- Inequitable conduct, if asserted
When did the parties file key motions in 1:18-cv-00149?
Featured snippet answer: Cannot be stated without verified docket dates.
Typical motion sequence to verify on the record
- Motion to dismiss / threshold motions
- Markman claim construction
- Summary judgment or partial summary judgment
- Daubert challenges and expert reports
- Preliminary injunction request, if any
What did the court decide in H. Lundbeck v. Torrent (D. Del.)?
Featured snippet answer: Cannot be stated without specific holdings from orders or opinions in this matter.
Claim construction and infringement conclusions
- Construction of key functional or composition terms
- Infringement model (product-by-process vs direct structural comparisons)
- Summary judgment posture and outcomes
Invalidity conclusions
- Anticipation by specific prior art references
- Obviousness combinations
- Enablement or written description findings
- §101 (if raised) and status of any eligibility analysis
Was there a settlement or consent judgment in 1:18-cv-00149?
Featured snippet answer: Cannot be determined from the information provided.
Settlement terms that matter commercially
- Stated or implied launch date carve-outs
- License scope (patent-by-patent or portfolio)
- Geographic limitations (US-only vs wider)
- Supply terms and “at-risk” entry restrictions
- Dismissal status of claims and mutual covenants
What is the Orange Book status of the Lundbeck drug involved in 1:18-cv-00149?
Featured snippet answer: Cannot be provided without knowing the specific reference listed drug (RLD) and the Orange Book patents tied to the litigation.
How to map Orange Book listings to the lawsuit
- Patent numbers listed for the RLD
- Expiration dates and any pediatric exclusivity extensions
- Orphan exclusivity and exclusivity “stacking” where applicable
- Match to Paragraph IV notice(s)
When does exclusivity or patent protection expire for the disputed Lundbeck product?
Featured snippet answer: Not determinable without the asserted patent list and/or the Orange Book patent numbers.
Exclusivity timelines to verify
- NDA/LA exclusivity end date
- Patent earliest expiry (and “latest” expiry across the relevant patents)
- Any PTA (patent term adjustment)
- Any pediatric extension under 21 U.S.C. §355a
What generic launch risks exist for Torrent based on the litigation outcome?
Featured snippet answer: Cannot be assessed without the procedural posture and outcome.
At-risk launch scenarios that depend on the case
- If Torrent prevailed: likely immediate or earlier entry risk
- If Lundbeck prevailed: design-around probability and injunction exposure
- If settlement: launch timing tied to contract terms and dismissed/withdrawn patents
How does this dispute compare with other Lundbeck v. generic cases?
Featured snippet answer: Comparison requires the drug/patent and holding specifics from 1:18-cv-00149 to anchor like-for-like comparisons.
Benchmark dimensions for a valid comparison
- Same Lundbeck portfolio or different drug(s)
- Same patent family or distinct families
- Same court judge and claim construction themes
- Same Paragraph IV notice strategy
Key Takeaways
- The prompt provides only the case caption and docket number (1:18-cv-00149) without any asserted patent numbers, court orders, holdings, or settlement indicators.
- A litigation summary that is accurate for R&D, licensing, or litigation decisions must cite: asserted patents, motion dates, claim construction outcomes, infringement/invalidity determinations, and final disposition.
- Those required facts are not present in the provided input.
FAQs
- What is the procedural posture of 1:18-cv-00149 and what dates control the next litigation deadline?
- Which Lundbeck Orange Book patents correspond to Torrent’s ANDA Paragraph IV notice in this case?
- Did the court issue a claim construction order in 1:18-cv-00149, and how did it affect the infringement analysis?
- Did the parties enter a settlement that impacts generic launch timing or design-around options?
- If Torrent lost, what injunction scope or remaining patents could still block entry?
References (APA)
- H. Lundbeck A/S v. Torrent Pharmaceuticals Limited, No. 1:18-cv-00149 (D. Del.).
